Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center. D. Spyratos (Thessaloniki, Greece), I. Tsiouprou (Thessaloniki, Greece), V. Tsartsianidou (Thessaloniki, Greece), S. Lampaki (Thessaloniki, Greece), E. Eleftheriadou (Thessaloniki, Greece), K. Domvri (Thessaloniki, Greece), T. Kontakiotis (Thessaloniki, Greece)
Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology
Disease area: Thoracic oncologyRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Spyratos (Thessaloniki, Greece), I. Tsiouprou (Thessaloniki, Greece), V. Tsartsianidou (Thessaloniki, Greece), S. Lampaki (Thessaloniki, Greece), E. Eleftheriadou (Thessaloniki, Greece), K. Domvri (Thessaloniki, Greece), T. Kontakiotis (Thessaloniki, Greece). Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center.. 4678
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020
Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020
Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011
Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer> Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021
Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007
Treatment of non-small cell lung cancer (NSCLC) - the state of the art and beyond Source: International Congress 2017 – State of the art session: "Lung cancer" Year: 2017
A non-small cell lung cancer modelling by endogenous κ-ras manipulation Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection Year: 2005
Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002
Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021
Gene expression analysis in patients with non-small cell lung cancer subjected to thoracotomy Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009
Detecting subtypes of non-small cell lung cancer by electronic nose. Source: International Congress 2018 – Lung cancer: from early diagnosis to modern monitoring strategies Year: 2018
Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018
Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis Source: ERJ Open Res, 5 (4) 00179-2019; 10.1183/23120541.00179-2019 Year: 2019
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Detection of non-small cell lung cancer by an electronic nose. Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017
Ras peptide-specific vaccination in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006
T790M-mutation in EGFR progressive non-small cell lung cancer, role of re-biopsy and ctDNA analysis Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017